QT Imaging Successfully Completes FDA Routine Inspection with Zero Observations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 20 hours ago
0mins
QT Imaging announced the successful completion of its first routine inspection by the FDA, with zero Form 483 observations. The FDA inspection reviewed QT Imaging's Quality Management System and related processes that support the company's operations, with no Form 483 observations issued. The inspector also provided positive feedback regarding the organization of QT Imaging's QMS and the company's responsiveness throughout the inspection process. An FDA Form 483 is issued at the conclusion of an inspection when an FDA investigator has observed conditions that may constitute violations of the Food, Drug and Cosmetic Act and related regulations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QTI
Wall Street analysts forecast QTI stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 3.910
Low
Averages
High
Current: 3.910
Low
Averages
High
About QTI
QT Imaging Holdings, Inc. is a medical device company engaged in the research, development, and commercialization of body imaging systems using low-frequency sound waves. The Company's products include QTI Breast Acoustic CT Scanner and QTviewer Software. QTI’s Breast Acoustic CT scanner with QTViewer viewer software is the only three-dimensional (3D) imaging device to receive United States Food and Drug Administration (FDA) clearance for use as a transmission and reflection ultrasonic imaging system of a patients breast. QTviewer is its proprietary image viewing and analysis platform, purpose-built to interpret the rich, quantitative datasets generated by the QTI Breast Acoustic CT™ scanner. The QTviewer allows users to rotate, zoom, and cross-navigate entire breast volumes. Whether isolating lesions or exploring architectural distortion, radiologists can interact with the data dynamically to gain an understanding of tissue structure and lesion morphology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
QT Imaging Successfully Completes FDA Inspection with Zero Observations
- Quality Management Validation: QT Imaging successfully completed its first FDA routine inspection with zero Form 483 observations, indicating the maturity of its Quality Management System and operational discipline, thereby enhancing the company's credibility in the medical device market.
- Significant Operational Achievement: COO Steve Choate stated that this inspection outcome represents an important operational milestone for the company, reflecting the dedication of the team and commitment to operational excellence, which is expected to facilitate future global commercialization expansion.
- Customer Base Support: As manufacturing scales and the customer base grows, QT Imaging will continue to uphold the highest standards of quality and regulatory compliance, which not only helps enhance customer satisfaction but also strengthens market competitiveness.
- Strategic Development Outlook: This successful inspection lays the groundwork for QT Imaging's future product development and market expansion, which is anticipated to drive long-term growth and innovation capabilities in the medical imaging sector.
See More
QT Imaging CEO Engages in Women's Health Forum
- Award Ceremony Appearance: QT Imaging CEO Dr. Raluca Dinu presented the Shiftmaker Award to tennis legend Martina Navratilova at the Sports Shiftmaker Awards, highlighting the company's commitment to women's health.
- Women's Health Discussions: During Wimbledon, Dr. Dinu participated in high-profile panels focused on women's health, emphasizing the importance of personalized healthcare solutions to drive innovation and investment in the sector.
- Industry Leaders Gather: The forums brought together global leaders from healthcare, investment, and academia to discuss the future of breast health and women's healthcare innovation, promoting the convergence of patient advocacy and technological advancements.
- Technological Commitment: QT Imaging's involvement underscores its dedication to improving breast health through innovative imaging technologies, aiming to enhance patient experiences and provide critical information for informed healthcare decisions.
See More
QT Imaging Reports Breakthrough in Quantitative Biomarkers for Breast Imaging
- Repeatability and Reproducibility Analysis: QT Imaging's study demonstrates less than 1% variability in speed of sound measurements across five patients scanned five times at multiple clinical sites, ensuring high reproducibility of biomarkers and enhancing clinical decision-making reliability.
- Volume Measurement Stability: Volumetric measurements derived from speed of sound image volumes show approximately 5% variability for Total Breast Volume (TBV) and 12% for the ratio of fibroglandular volume to total breast volume (FGV/TBV), highlighting QT Imaging's advantages in breast imaging.
- Comparison with Industry Benchmarks: The variability demonstrated by QT Imaging is significantly lower than the 11% to 22% reported for other breast MRI biomarkers, indicating the potential of its technology to provide consistency and reliability, which may drive its market adoption.
- Advancing Precision Medicine: The CEO of QT Imaging stated that the low variability supports the stability of its platform, aiding the company in achieving objective, reproducible, data-driven assessments in breast imaging, thereby advancing the field of precision medicine.
See More
QT Imaging Secures Saudi Approval for Breast Imaging Technology Deployment
- Market Access Milestone: QT Imaging's Breast Acoustic CT™ scanner has received approval from the Saudi Food and Drug Authority (SFDA), marking a significant step in the company's commercialization efforts in one of the largest healthcare markets in the Middle East, which is expected to significantly enhance the company's market share in the region.
- Exclusive Distribution Agreement: The company has entered into an exclusive distribution agreement with Gulf Medical, a leading healthcare technology provider in Saudi Arabia, ensuring rapid commercial activities following SFDA approval, thereby expanding its business network in the Kingdom.
- Investment in Women's Health: Saudi Arabia continues to invest heavily in women's health and healthcare modernization under its Vision 2030 framework, with breast cancer being the most commonly diagnosed cancer among women in the Kingdom, driving an increasing demand for advanced imaging technologies.
- International Expansion Strategy: This approval not only lays the groundwork for QT Imaging's commercial deployment in Saudi Arabia but also enhances its growth potential in the Middle East and global markets, showcasing the company's ability to successfully navigate international regulatory pathways.
See More
QT Imaging Raises $10 Million in Public Offering
- Offering Size: QT Imaging announced a public offering of 2,000,000 shares at $5.00 per share, aiming to raise approximately $10 million, reflecting strong investor confidence in the company's strategic direction.
- Use of Proceeds: The funds will be allocated for working capital and general corporate purposes, and the extension of the maturity date of the senior secured term loan by two years enhances the company's financial flexibility to support its commercial and strategic growth initiatives.
- Underwriting Arrangement: Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager, with Northland Capital Markets as co-manager, ensuring professionalism and market credibility for the offering.
- Compliance Statement: The offering is conducted under a registration statement with the SEC, expected to close around May 18, 2026, demonstrating the company's commitment to compliance and transparency.
See More
QT Imaging Q1 2026 Earnings Call Highlights
- Revenue Growth: In Q1 2026, QT Imaging reported revenue of $6.5 million, primarily driven by the shipment of 13 QT Breast Acoustic CT systems, indicating a strong market demand response, with an expected annual revenue of approximately $39 million.
- Loan Extension: The maturity date of the senior secured term loan with Lynrock Lake has been extended to March 31, 2029, although the interest rate increased from 10% to 12% per annum, this move provides the company with greater financial flexibility to support future expansion.
- Regulatory Milestone: QT Imaging achieved an important milestone with the approval of a new Category III CPT code by the American Medical Association, effective January 1, 2027, which is expected to enhance product acceptance in the market and drive revenue growth.
- Software Innovation: The launch of the QT Imaging-Olea Viewer and software version 4.5.0 significantly improves imaging resolution and visualization of posterior breast tissue, which is anticipated to enhance customer experience and drive sales growth.
See More
QT Imaging Successfully Completes FDA Inspection with Zero Observations
- Quality Management Validation: QT Imaging successfully completed its first FDA routine inspection with zero Form 483 observations, indicating the maturity of its Quality Management System and operational discipline, thereby enhancing the company's credibility in the medical device market.
- Significant Operational Achievement: COO Steve Choate stated that this inspection outcome represents an important operational milestone for the company, reflecting the dedication of the team and commitment to operational excellence, which is expected to facilitate future global commercialization expansion.
- Customer Base Support: As manufacturing scales and the customer base grows, QT Imaging will continue to uphold the highest standards of quality and regulatory compliance, which not only helps enhance customer satisfaction but also strengthens market competitiveness.
- Strategic Development Outlook: This successful inspection lays the groundwork for QT Imaging's future product development and market expansion, which is anticipated to drive long-term growth and innovation capabilities in the medical imaging sector.
See More
QT Imaging CEO Engages in Women's Health Forum
- Award Ceremony Appearance: QT Imaging CEO Dr. Raluca Dinu presented the Shiftmaker Award to tennis legend Martina Navratilova at the Sports Shiftmaker Awards, highlighting the company's commitment to women's health.
- Women's Health Discussions: During Wimbledon, Dr. Dinu participated in high-profile panels focused on women's health, emphasizing the importance of personalized healthcare solutions to drive innovation and investment in the sector.
- Industry Leaders Gather: The forums brought together global leaders from healthcare, investment, and academia to discuss the future of breast health and women's healthcare innovation, promoting the convergence of patient advocacy and technological advancements.
- Technological Commitment: QT Imaging's involvement underscores its dedication to improving breast health through innovative imaging technologies, aiming to enhance patient experiences and provide critical information for informed healthcare decisions.
See More
QT Imaging Reports Breakthrough in Quantitative Biomarkers for Breast Imaging
- Repeatability and Reproducibility Analysis: QT Imaging's study demonstrates less than 1% variability in speed of sound measurements across five patients scanned five times at multiple clinical sites, ensuring high reproducibility of biomarkers and enhancing clinical decision-making reliability.
- Volume Measurement Stability: Volumetric measurements derived from speed of sound image volumes show approximately 5% variability for Total Breast Volume (TBV) and 12% for the ratio of fibroglandular volume to total breast volume (FGV/TBV), highlighting QT Imaging's advantages in breast imaging.
- Comparison with Industry Benchmarks: The variability demonstrated by QT Imaging is significantly lower than the 11% to 22% reported for other breast MRI biomarkers, indicating the potential of its technology to provide consistency and reliability, which may drive its market adoption.
- Advancing Precision Medicine: The CEO of QT Imaging stated that the low variability supports the stability of its platform, aiding the company in achieving objective, reproducible, data-driven assessments in breast imaging, thereby advancing the field of precision medicine.
See More
QT Imaging Secures Saudi Approval for Breast Imaging Technology Deployment
- Market Access Milestone: QT Imaging's Breast Acoustic CT™ scanner has received approval from the Saudi Food and Drug Authority (SFDA), marking a significant step in the company's commercialization efforts in one of the largest healthcare markets in the Middle East, which is expected to significantly enhance the company's market share in the region.
- Exclusive Distribution Agreement: The company has entered into an exclusive distribution agreement with Gulf Medical, a leading healthcare technology provider in Saudi Arabia, ensuring rapid commercial activities following SFDA approval, thereby expanding its business network in the Kingdom.
- Investment in Women's Health: Saudi Arabia continues to invest heavily in women's health and healthcare modernization under its Vision 2030 framework, with breast cancer being the most commonly diagnosed cancer among women in the Kingdom, driving an increasing demand for advanced imaging technologies.
- International Expansion Strategy: This approval not only lays the groundwork for QT Imaging's commercial deployment in Saudi Arabia but also enhances its growth potential in the Middle East and global markets, showcasing the company's ability to successfully navigate international regulatory pathways.
See More
QT Imaging Raises $10 Million in Public Offering
- Offering Size: QT Imaging announced a public offering of 2,000,000 shares at $5.00 per share, aiming to raise approximately $10 million, reflecting strong investor confidence in the company's strategic direction.
- Use of Proceeds: The funds will be allocated for working capital and general corporate purposes, and the extension of the maturity date of the senior secured term loan by two years enhances the company's financial flexibility to support its commercial and strategic growth initiatives.
- Underwriting Arrangement: Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager, with Northland Capital Markets as co-manager, ensuring professionalism and market credibility for the offering.
- Compliance Statement: The offering is conducted under a registration statement with the SEC, expected to close around May 18, 2026, demonstrating the company's commitment to compliance and transparency.
See More
QT Imaging Q1 2026 Earnings Call Highlights
- Revenue Growth: In Q1 2026, QT Imaging reported revenue of $6.5 million, primarily driven by the shipment of 13 QT Breast Acoustic CT systems, indicating a strong market demand response, with an expected annual revenue of approximately $39 million.
- Loan Extension: The maturity date of the senior secured term loan with Lynrock Lake has been extended to March 31, 2029, although the interest rate increased from 10% to 12% per annum, this move provides the company with greater financial flexibility to support future expansion.
- Regulatory Milestone: QT Imaging achieved an important milestone with the approval of a new Category III CPT code by the American Medical Association, effective January 1, 2027, which is expected to enhance product acceptance in the market and drive revenue growth.
- Software Innovation: The launch of the QT Imaging-Olea Viewer and software version 4.5.0 significantly improves imaging resolution and visualization of posterior breast tissue, which is anticipated to enhance customer experience and drive sales growth.
See More
